Chatziralli Irini, Maniatea Aggeliki, Koubouni Kyriakoula, Parikakis Efstratios, Mitropoulos Panagiotis
2 Department of Ophthalmology, Ophthalmiatrion Athinon, Athens - Greece.
Eur J Ophthalmol. 2017 Mar 10;27(2):215-219. doi: 10.5301/ejo.5000863. Epub 2016 Sep 7.
To evaluate the potential efficacy and safety of primary intravitreal ranibizumab in patients with symptomatic retinal arterial macroaneurysm (RAM).
This prospective study comprised 5 eyes with RAM treated with intravitreal ranibizumab. At baseline, all patients underwent best-corrected visual acuity (BCVA) measurement, ophthalmic examination including slit-lamp biomicroscopy, and central foveal thickness (CFT) measurement using optical coherence tomography. Fluorescein angiography was also performed to confirm diagnosis. Patients were examined at 1 month after injection and monthly thereafter. Main outcome measures included changes in BCVA and CFT. Safety was assessed by ophthalmic examination and report of systemic adverse effects.
There was a statistically significant difference in BCVA (p<0.001) and CFT (p<0.001) before and after the ranibizumab injection at the end of the follow-up of 13.4 ± 3.2 months. One injection appeared to be sufficient for the resolution of macular edema and absorption of hemorrhages. No observable ocular or systemic side effects were found. One patient developed foveal atrophy.
Intravitreal ranibizumab seems to be effective and safe for the treatment of symptomatic RAM.
评估玻璃体内注射雷珠单抗治疗有症状视网膜动脉大动脉瘤（RAM）患者的潜在疗效和安全性。
这项前瞻性研究纳入了5例接受玻璃体内注射雷珠单抗治疗的RAM患者。基线时，所有患者均接受最佳矫正视力（BCVA）测量、包括裂隙灯生物显微镜检查在内的眼科检查以及使用光学相干断层扫描测量中心凹厚度（CFT）。还进行了荧光素血管造影以确诊。患者在注射后1个月进行检查，之后每月检查一次。主要观察指标包括BCVA和CFT的变化。通过眼科检查和全身不良反应报告评估安全性。
在13.4±3.2个月的随访结束时，注射雷珠单抗前后的BCVA（p<0.001）和CFT（p<0.001）有统计学显著差异。一次注射似乎足以消退黄斑水肿和吸收出血。未发现明显的眼部或全身副作用。1例患者出现黄斑萎缩。
玻璃体内注射雷珠单抗治疗有症状的RAM似乎有效且安全。
